TREVENA,INC. (NASDAQ:TRVN) Files An 8-K Results of Operations and Financial Condition
Item2.02. Results of Operations and
Financial Condition.
The information under this caption and contained in the press
release attached hereto as Exhibit99.1 is furnished by
Trevena,Inc. (the Company) in accordance with Securities Exchange
Commission Release No.33-8216. This information shall not be
deemed filed for purposes of Section18 of the Securities Exchange
Act of 1934, as amended (the Exchange Act), or incorporated by
reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act whether made before or after the
date of this Current Report, except as shall be expressly set
forth by specific reference in such a filing.
OnMay4, 2017, the Company issued a press release announcing its
financial results for the quarter endedMarch31, 2017. A copy of
the press release is furnished hereto as Exhibit99.1 and
incorporated herein by reference.
Item9.01. Financial Statements and
Exhibits.
(d) Exhibits
|
Number |
|
Description |
|
99.1 |
Press Release dated May4, 2017 |
About TREVENA, INC. (NASDAQ:TRVN)
Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties. TREVENA, INC. (NASDAQ:TRVN) Recent Trading Information
TREVENA, INC. (NASDAQ:TRVN) closed its last trading session down -0.05 at 3.39 with 773,715 shares trading hands.
